{"id":"qtorin-3-9-rapamycin-anhydrous-gel","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Skin burning sensation"},{"rate":"10-20%","effect":"Skin redness"},{"rate":"5-10%","effect":"Skin itching"}]},"_chembl":{"chemblId":"CHEMBL413","moleculeType":"Small molecule","molecularWeight":"914.19"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rapamycin, the active ingredient in QTORIN, binds to the mTOR complex, inhibiting its activity and leading to immunosuppressive effects. This mechanism is thought to be responsible for the therapeutic benefits of QTORIN in treating atopic dermatitis.","oneSentence":"QTORIN 3.9% rapamycin anhydrous gel is a topical immunomodulator that targets the mTOR pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:52.717Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT06653842","phase":"PHASE2","title":"A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2024-12-20","conditions":"Cutaneous Venous Malformations","enrollment":15},{"nctId":"NCT06239480","phase":"PHASE3","title":"SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2024-07-31","conditions":"Microcystic Lymphatic Malformation","enrollment":51},{"nctId":"NCT05180708","phase":"PHASE3","title":"A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita","status":"COMPLETED","sponsor":"Palvella Therapeutics, Inc.","startDate":"2021-11-29","conditions":"Pachyonychia Congenita","enrollment":87},{"nctId":"NCT05643872","phase":"PHASE3","title":"A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita","status":"RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2022-11-15","conditions":"Pachyonychia Congenita","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"QTORIN 3.9% rapamycin anhydrous gel","genericName":"QTORIN 3.9% rapamycin anhydrous gel","companyName":"Palvella Therapeutics, Inc.","companyId":"palvella-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"QTORIN 3.9% rapamycin anhydrous gel is a topical immunomodulator that targets the mTOR pathway. Used for Moderate to severe atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}